Amicus inks gene therapy deals with Thermo Fisher and Catalent

Amicus Therapeutics has found CDMO partners to manufacture its gene therapies. 

Amicus announced this week that it has finalized a strategic manufacturing agreement with Brammer Bio, a part of Thermo Fisher, who will take over research and development production for the company’s Batten disease program. Under the agreement, the two companies will also collaborate to develop and manufacture a broader portfolio of AAV gene therapy programs. 

"We are thrilled to begin working with Amicus and to contribute to the successful development of their gene therapy pipeline," Chris Murphy, vice president and general manager, viral vector services at Thermo Fisher Scientific, said in a statement. "We see this as a strong strategic relationship to enable manufacturing of a deep gene therapy pipeline across various stages of development for people with devastating genetic diseases.”

A day after the Thermo Fisher announcement, Amicus also stated that it has entered a collaboration with Paragon Gene Therapy, a unit of Catalent Biologics. As part of that partnership, the companies will work on developing Amicus’ program for Pompe disease and its adeno-associated virus manufacturing platform.

Read the press release.